Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

This Under-the-Radar COVID Vaccine Stock Has a Tesla Tie-In

By Keith Speights - Nov 27, 2020 at 6:10AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

And it's not too far behind coronavirus vaccine leaders Pfizer and Moderna.

Tesla ( TSLA -6.42% ) is sizzling-hot right now. It will soon become the latest addition to the S&P 500. The company reported record revenue and earnings in the third quarter of 2020. Its CEO, Elon Musk, just edged out Bill Gates to become the second-richest person in the world, thanks to his Tesla stock skyrocketing.

It seems that nearly anyone or anything connected with Tesla achieves success. That could be fantastic news for one biotech that's closing in on the leaders in the race to develop a coronavirus vaccine. CureVac ( CVAC -0.84% ) is something of an under-the-radar COVID-19 vaccine maker for U.S. investors, but it's the only one to have a bona fide Tesla tie-in.

Tesla charging station.

Image source: Tesla.

Printing mRNA

You might think it's a big stretch for an electric vehicle company like Tesla to have anything to do with a biotech developing a coronavirus vaccine. Once you understand a few key things about CureVac and Tesla, the connection between the two companies will make sense. 

Like Moderna and Pfizer's partner BioNTech, CureVac develops vaccines and therapies based on messenger RNA (mRNA). This mRNA approach holds significant potential in immunizing against infections by multiple types of viruses as well as treating other diseases, including cancer.

In 2019 (well before the COVID-19 pandemic struck), CureVac won $34 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to build a prototype mRNA "printer."  The idea was to create a device that could produce mRNA doses for use in regions with viral outbreaks and in hospitals for making personalized medicines.

An mRNA printer would be a revolutionary leap forward in fighting viral disease, especially in remote areas. As you might expect, though, there are plenty of technological hurdles to developing the device.

That's where Tesla enters the picture. Three years ago, Tesla acquired Grohmann Engineering, a German company that specializes in automated manufacturing. After CureVac received CEPI funding to build a prototype mRNA printer, Tesla Grohmann Automation was the logical partner to turn to for help.

So far, CureVac hasn't said very much on how the effort to develop an mRNA printer is going. We'll have to wait and see if Tesla's magic will show up once again by helping the biotech achieve a breakthrough.

CureVac's bigger story

However, CureVac won't need Tesla's Midas touch to succeed with its bigger story. It's one of only three companies with COVID-19 vaccine candidates currently in phase 2 testing. The other two are Chinese drugmakers. This puts CureVac's vaccine candidate CVnCoV behind only five others in late-stage testing that could be commercialized in major Western markets.

CureVac plans to advance CVnCOV into a pivotal phase 2b/3 clinical study by the end of 2020. If all goes well, the biotech seems likely to become one of the biggest COVID vaccine winners.

The company recently lined up an agreement with the European Commission to supply up to 225 million doses of CVnCOV (assuming it secures regulatory approval). The deal includes an option for the EC to buy an additional 180 million doses. Although no financial details were revealed, CureVac likely stands to make several billion dollars in 2021 if CVnCOV is proven to be safe and effective in late-stage testing. 

CVnCOV can be stored at standard refrigerator temperatures for up to three months and for up to 24 hours at room temperature. This could give it an advantage over vaccines such as Pfizer's and BioNTech's BNT162b2, which must be stored at ultracold temperatures. 

One to watch

Success for CVnCOV could bode well for the rest of CureVac's mRNA pipeline. The company is evaluating a rabies vaccine and two cancer immunotherapy candidates in phase 1 clinical studies. CureVac also has several other preclinical programs.

It's still too early to know for sure if CVnCOV will achieve similar efficacy to the results announced by Pfizer and Moderna. However, CureVac is without question a biotech stock for investors to keep on their radars.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

CureVac N.V. Stock Quote
CureVac N.V.
$43.58 (-0.84%) $0.37
Tesla, Inc. Stock Quote
Tesla, Inc.
$1,014.97 (-6.42%) $-69.63

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/04/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.